GLP-1 receptor agonists have become the most talked-about class of medications in a generation. Ozempic (semaglutide) and Mounjaro (tirzepatide) have gone from diabetes management tools to a cultural phenomenon — with celebrity endorsements, shortages, and fierce debate about whether they're a revolution or overhyped.
As a physician with decades of clinical experience, I want to give you what the internet rarely provides: an honest, evidence-grounded look at what these drugs do, who they're genuinely appropriate for, what the real risks are, and what to ask your doctor before considering them.
What are GLP-1 Receptor Agonists?
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It signals your pancreas to release insulin, slows gastric emptying (how quickly food leaves your stomach), and critically — acts on the brain's hunger and satiety centers to reduce appetite.
GLP-1 receptor agonists are drugs that mimic or amplify this hormone. The major approved agents include:
- Semaglutide (Ozempic/Wegovy) — weekly injection; Ozempic is FDA-approved for Type 2 diabetes, Wegovy for chronic weight management
- Tirzepatide (Mounjaro/Zepbound) — dual GIP/GLP-1 agonist; weekly injection; Mounjaro for T2DM, Zepbound for obesity
- Liraglutide (Victoza/Saxenda) — daily injection; older agent, less weight loss efficacy
- Oral semaglutide (Rybelsus) — daily tablet, lower bioavailability than injection
What the Evidence Actually Shows
The STEP trials for semaglutide and the SURMOUNT trials for tirzepatide are legitimately impressive. In the SURMOUNT-1 trial, participants on tirzepatide 15mg lost an average of 22.5% of body weight over 72 weeks — numbers that approach bariatric surgery outcomes without surgery.
Beyond weight loss, the cardiovascular data is compelling. The SELECT trial showed semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in people with overweight/obesity and established cardiovascular disease — even without diabetes. That is clinically significant.
"The data is among the strongest we've seen for any weight loss intervention. The question isn't whether it works — it's whether it's appropriate for you, and whether you're prepared for what it requires long term."
Who Is a Good Candidate?
Current FDA approvals and clinical guidelines support GLP-1 medications for:
- Type 2 diabetes (all injectable GLP-1 agents)
- Adults with a BMI ≥30, or BMI ≥27 with at least one weight-related condition (hypertension, sleep apnea, T2DM, dyslipidemia)
- Adults with established cardiovascular disease who are overweight or obese (semaglutide specifically)
If you do not meet these criteria, you are using these medications off-label. That's not automatically wrong — physicians prescribe off-label constantly — but it does mean the risk/benefit calculation is less established.
Real Risks You Should Know
The side effect profile is predominantly gastrointestinal — nausea, vomiting, diarrhea, and constipation. These typically peak in the first 4–12 weeks as doses are titrated up. Most people tolerate them; about 10% discontinue due to side effects.
The more significant concerns that deserve honest discussion:
- Muscle mass loss: A meaningful portion of the weight lost on GLP-1 medications is lean muscle, not just fat. Resistance training and adequate protein intake are not optional — they are essential if you use these drugs.
- Thyroid C-cell tumors: Observed in rodent studies; clinical significance in humans remains uncertain. These drugs carry a black box warning and should not be used in people with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
- Pancreatitis: Rare but observed; requires medical attention if severe abdominal pain develops.
- Weight regain on discontinuation: Multiple studies show significant weight regain — often 2/3 of lost weight — within one year of stopping. This is a long-term medication for most people, not a short course.
- Cost and access: Without insurance coverage, these drugs can cost $900–$1,300/month. Coverage is inconsistent and politically contested.
📋 Affiliate Disclosure — Sponsored Resource
Considering a GLP-1 Program?
Hims/Hers Medical offers physician-supervised semaglutide programs with regular check-ins and built-in monitoring. I recommend any GLP-1 program be medically supervised. If you'd like to explore options:
Explore Supervised GLP-1 Programs →Questions to Ask Your Doctor
If you're considering a GLP-1 medication, come prepared with these questions:
- Am I an appropriate candidate based on my BMI, comorbidities, and cardiovascular risk?
- Which specific agent — and which dose titration schedule — makes sense for my situation?
- What monitoring do I need while on this medication (labs, blood pressure, etc.)?
- What is the plan if I want to stop? What is the discontinuation strategy?
- How do we protect my muscle mass during treatment?
- What does my insurance cover, and what are my out-of-pocket costs?
The Bottom Line
GLP-1 medications represent a genuine advance in the treatment of obesity, Type 2 diabetes, and cardiovascular risk reduction. The data is compelling. But they are powerful medications with real side effects, significant costs, and a long-term commitment requirement that many people don't fully understand going in.
They are not for everyone. They are not a shortcut. And they work best as one component of a broader metabolic health strategy — not a replacement for it.
If you have specific questions about your situation, please consult your physician. That conversation is the one that actually matters.